# A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06709131** · PHASE1 · SUSPENDED · sponsor: **He Huang** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia(AML)

## Interventions

- **DRUG:** CAR-T cells（ chimeric antigen receptor T cells）

## Key facts

- **NCT ID:** NCT06709131
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-01-08
- **Primary completion:** 2025-08-17
- **Final completion:** 2026-08-17
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** Product manufacturing process improvement
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709131, "A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06709131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*